Overall, definitive focal brachytherapy has a favorable toxicity profile. Oncologic outcomes are yet to mature. The evidence is limited by the small number of studies with low patients' number, across study heterogeneity, and possibility of publication bias.
Keyphrases
- minimally invasive
- prostate cancer
- locally advanced
- high dose
- end stage renal disease
- radiation therapy
- radical prostatectomy
- ejection fraction
- chronic kidney disease
- newly diagnosed
- oxidative stress
- prognostic factors
- peritoneal dialysis
- single cell
- squamous cell carcinoma
- type diabetes
- adipose tissue
- low dose
- patient reported